Rockwell Medical(US:RMTI) Benzinga·2026-01-20 15:18Core Viewpoint - Rockwell Medical, Inc. reported strong preliminary financial results for Q4 2025, indicating a positive trajectory towards profitability and long-term stability [1][3]. Financial Performance - Q4 2025 sales are expected to reach approximately $18.6 million, surpassing the Street consensus estimate of $16.55 million [1]. - Full-year revenue for 2025 is projected to be around $69.5 million [1]. - The company anticipates a gross margin of about 22% for Q4 2025, an increase from 14% in Q3 2025 [1]. Operational Highlights - Rockwell Medical achieved adjusted EBITDA positivity and generated positive operating cash flow of roughly $2.3 million during the quarter [2]. - The company expects to have cash, cash equivalents, and available-for-sale investments totaling about $25 million at year-end [2]. Strategic Outlook - Management emphasizes a focus on sales growth, improved profitability, and product diversification as part of its long-term strategy for 2026 [3]. Stock Performance - Rockwell Medical shares increased by 22.22% to $1.17 at the time of publication, although the stock has declined over 56% in the past year [4].